InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,892.00
(
-0.99%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.33
(
0.12%
)
Bitcoin
63,814.24
(
-0.73%
)
Post# of 17106
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mick

Send PM Follow Ignore
Followers 3156
Posts 961092
Boards Moderated 205
Alias Born 09/04/2000

mick

Member Level

Re: mick post# 16222

Wednesday, 10/11/2017 5:59:07 PM

Wednesday, October 11, 2017 5:59:07 PM

Post# of 17106
#1/ On Thursday, as Biogen’s former hemophilia business makes its Nasdaq debut, the market will decide whether the fledgling spinoff is worth its $5 billion valuation.

Called Bioverativ, the company is setting out with Biogen’s two approved hemophilia drugs, about $325 million in cash, and plans to grow into a biotech mainstay. Those two drugs — Eloctate and Alprolix — brought in more than $800 million last year, and analysts expect them to generate a cumulative $1 billion in

https://www.statnews.com/2017/02/02/biogen-spinof/?utm_campaign=trendmd
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up